GV has contributed to two rounds for the gene-editing technology developer, which publicly launched yesterday with $315m of funding.
US-based gene-editing technology developer Prime Medicine emerged from stealth yesterday with $315m of series A and B funding from investors including GV, a corporate venturing subsidiary of internet and technology group Alphabet.
The company raised $115m in a series A round backed by GV, Arch Venture Partners, Newpath Partners and investment and financial services group Fidelity’s F-Prime Capital unit.
Prime Medicine concurrently unveiled a $200m series B round featuring all the series A investors in addition to Casdin Capital, Cormorant…
